8-K: Revelation Biosciences' Gemini Shows Promise in Attenuating Inflammation in Preclinical Study

Revelation Biosciences announces positive preclinical results for its drug candidate Gemini, demonstrating a significant attenuation of inflammatory responses in human peripheral blood mononuclear cells.

Summary

• Revelation Biosciences announced that its drug candidate Gemini significantly attenuated inflammatory responses in human peripheral blood mononuclear cells (PBMCs) in a preclinical study.
• The study involved priming human PBMCs with Gemini or a placebo, followed by exposure to HMGB-1 (a tissue injury marker) and LPS (a bacterial infection marker).
• Gemini priming resulted in a significant decrease in pro-inflammatory cytokines and a significant increase in anti-inflammatory cytokines compared to the placebo.
• The company anticipates demonstrating the same protective effect in patients treated with Gemini in its Phase 1b clinical study, with top-line data expected by mid-2025.
• This Phase 1b study, called PRIME, involves patients with Stage 3 and 4 Chronic Kidney Disease (CKD).
• The data from the PRIME clinical study will support future development of the GEM-CKD, GEM-AKI, and GEM-PSI programs.
• Gemini is being developed for multiple indications, including preventing acute kidney injury (GEMINI-AKI), preventing post-surgical infection (GEMINI-PSI), and treating chronic kidney disease (GEMINI-CKD).

Sentiment

Score: 7

Explanation: The announcement highlights positive preclinical results, suggesting potential for Gemini in treating inflammation-related conditions. The anticipation of similar results in the Phase 1b study further contributes to a positive outlook, although the inherent risks associated with drug development temper the overall sentiment.

Positives

• Preclinical results show Gemini attenuates inflammation in human peripheral blood mononuclear cells.
• The company anticipates demonstrating the same protective effect in patients treated with Gemini in its Phase 1b clinical study.
• Gemini has potential applications in preventing acute kidney injury, post-surgical infection, and treating chronic kidney disease.
• The primary safety endpoint was met in the Phase 1 study, and results demonstrated statistically significant pharmacodynamic activity as observed through expected changes in multiple biomarkers including upregulation of IL-10.

Risks

• The forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially.
• These risks include competition, the ability to manage growth, the successful development of product candidates, and the outcome of clinical data.

Future Outlook

Revelation anticipates demonstrating the same protective effect in patients treated with Gemini in its Phase 1b clinical study, with top-line data expected by mid-2025. Data from the PRIME clinical study will support future development of the GEM-CKD, GEM-AKI and GEM-PSI programs.

Management Comments

• 'These exciting results further demonstrate the game-changing potential of Gemini to attenuate the inflammatory response to clinically relevant DAMPS and PAMPS,' said James Rolke, Chief Executive Officer of Revelation.
• 'We look forward to demonstrating the same protective effect in cells collected from CKD patients, which will be an excellent surrogate of future efficacy of Gemini in our target indications.'

Industry Context

This announcement is relevant to the broader pharmaceutical industry, particularly companies focused on developing treatments for inflammatory diseases and kidney-related conditions. The results could position Revelation Biosciences as a potential player in the market for therapies targeting inflammation-mediated damage.

Comparison to Industry Standards

• It's difficult to directly compare Revelation's preclinical results to industry standards without knowing the specific benchmarks used for similar drugs in development.
• However, the company's focus on attenuating inflammation through reprogramming the innate immune system aligns with a growing trend in immunotherapy and targeted therapies.
• Companies like Kiniksa Pharmaceuticals and InflaRx are also developing therapies targeting inflammatory pathways, but their specific mechanisms of action and target indications may differ from Gemini.
• The Phase 1b study in CKD patients will provide more relevant data for comparison to existing treatments and therapies in development for kidney disease.

Stakeholder Impact

• Positive results could benefit shareholders through increased stock value.
• Successful development of Gemini could provide a new treatment option for patients with AKI, CKD, and those at risk of post-surgical infections.
• Positive clinical trial outcomes could lead to increased employment opportunities within Revelation Biosciences.

Next Steps

• Revelation anticipates demonstrating the same protective effect in patients treated with Gemini in its Phase 1b clinical study.
• Top-line data from the PRIME Phase 1b clinical study in CKD patients is expected by mid-2025.
• The company intends to share the full results from the preclinical study in a future publication.
• Data from the PRIME clinical study will support future development of the GEM-CKD, GEM-AKI, and GEM-PSI programs.

Key Dates